Cell surface GRP78: A potential marker of good prognosis and response to chemotherapy in breast cancer

Oncology Letters

Volumn 10, Issue 4, 2015, Pages 2149-2155

  Yerushalmi, Rinat ^a,b   Raiter, Annat ^b   Nalbandyan, Karen ^a   Hardy, Britta ^b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

78 kDa glucose regulated protein; Breast cancer; Neoadjuvant treatment; Predictive marker; Prognostic marker

Indexed keywords

CELL SURFACE PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GLUCOSE REGULATED PROTEIN 78; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P53;

ADULT; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER STAGING; CLINICAL ARTICLE; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PROTEIN EXPRESSION; SCORING SYSTEM; TUMOR VOLUME;

EID: 84940022144     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2015.3579     Document Type: Article

References (39)

1. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al: Molecular portraits of human breast tumours. Nature 406: 747-752, 2000.
2. Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE Jr, Martino S, Mamounas EP, Kaufman PA and Wolmark N: Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: Joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 29: 3366-3373, 2011.
3. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 352: 930-942, 1998.
4. Sato M, Yao VJ, Arap W and Pasqualini R: GRP78 signaling hub a receptor for targeted tumor therapy. Adv Genet 69: 97-114, 2010.
5. Arap MA, Lahdenranta J, Mintz PJ, Hajitou A, Sarkis AS, Arap W and Pasqualini R: Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands. Cancer Cell 6: 275-284, 2004.
6. Lee AS: GRP78 induction in cancer: Therapeutic and prognostic implications. Cancer Res 67: 3496-3499, 2007.
7. Li J and Lee AS: Stress induction of GRP78/BiP and its role in cancer. Curr Mol Med 6: 45-54, 2006.
8. Gonzalez-Gronow M, Cuchacovich M, Llanos C, Urzua C, Gawdi G and Pizzo SV: Prostate cancer cell proliferation in vitro is modulated by antibodies against glucose-regulated protein 78 isolated from patient serum. Cancer Res 66: 11424-11431, 2006.
9. Rauschert N, Brändlein S, Holzinger E, Hensel F, Müller-Hermelink HK and Vollmers HP: A new tumor-specific variant of GRP78 as target for antibody-based therapy. Lab Invest 88: 375-386, 2008.
10. Chinni SR, Falchetto R, Gercel-Taylor C, Shabanowitz J, Hunt DF and Taylor DD: Humoral immune responses to cathepsin D and glucose-regulated protein 78 in ovarian cancer patients. Clin Cancer Res 3: 1557-1564, 1997.
11. Papalas JA, Vollmer RT, Gonzalez-Gronow M, Pizzo SV, Burchette J, Youens KE, Johnson KB and Selim MA: Patterns of GRP78 and MTJ1 expression in primary cutaneous malignant melanoma. Mod Pathol 23: 134-143, 2010.
12. Zhang LH, Yang XL, Zhang X, Cheng JX and Zhang W: Association of elevated GRP78 expression with increased astrocytoma malignancy via Akt and ERK pathways. Brain Res 1371: 23-31, 2011.
13. Ni M, Zhang Y and Lee AS: Beyond the endoplasmic reticulum: Atypical GRP78 in cell viability, signalling and therapeutic targeting. Biochem J 434: 181-188, 2011.
14. Uramoto H, Sugio K, Oyama T, Nakata S, Ono K, Yoshimastu T, Morita M and Yasumoto K: Expression of endoplasmic reticulum molecular chaperone Grp78 in human lung cancer and its clinical significance. Lung Cancer 49: 55-62, 2005.
15. Hsu WM, Hsieh FJ, Jeng YM, Kuo ML, Tsao PN, Lee H, Lin MT, Lai HS, Chen CN, Lai DM, et al: GRP78 expression correlates with histologic differentiation and favorable prognosis in neuroblastic tumors. Int J Cancer 113: 920-927, 2005.
16. Dong D, Ko B, Baumeister P, Swenson S, Costa F, Markland F, Stiles C, Patterson JB, Bates SE and Lee AS: Vascular targeting and antiangiogenesis agents induce drug resistance effector GRP78 within the tumor microenvironment. Cancer Res 65: 5785-5791, 2005.
17. Lee E, Nichols P, Spicer D, Groshen S, Yu MC and Lee AS: GRP78 as a novel predictor of responsiveness to chemotherapy in breast cancer. Cancer Res 66: 7849-7853, 2006.
18. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-2826, 2004.
19. Yarbro JW, Page DL, Fielding LP, Partridge EE and Murphy GP: American Joint Committee on Cancer prognostic factors consensus conference. Cancer 86: 2436-2446, 1999.
20. Iyalomhe GB and Imomoh PA. Ethics of clinical trials. Niger J Med 16: 301-306, 2007.
21. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, et al: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101: 736-750, 2009.
22. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM and Nielsen TO: Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14: 1368-1376, 2008.
23. Weidner N, Cote RJ, Suster S and Weiss LM (eds): Modern Surgical Pathology. 2nd edition. Elsevier Saunders, Philadelphia, PA, 2009.
24. Baptista MZ, Sarian LO, Vassallo J, Pinto GA, Soares FA and de Souza GA: Prognostic significance of GRP78 expression patterns in breast cancer patients receiving adjuvant chemotherapy. Int J Biol Markers 26: 188-196, 2011.
25. Yang L, Yang S, Liu J, Wang X, Ji J, Cao Y, Lu K, Wang J and Gao Y: Expression of GRP78 predicts taxane-based therapeutic resistance and recurrence of human gastric cancer. Exp Mol Pathol 96: 235-241, 2014.
26. Zheng YZ, Cao ZG, Hu X and Shao ZM: The endoplasmic reticulum stress markers GRP78 and CHOP predict disease-free survival and responsiveness to chemotherapy in breast cancer. Breast Cancer Res Treat 145: 349-358, 2014.
27. Hardy B, Raiter A, Yakimov M, Vilkin A and Niv Y: Colon cancer cells expressing cell surface GRP78 as a marker for reduced tumorigenicity. Cell Oncol (Dordr) 35: 345-354, 2012.
28. Díaz Flaqué MC, Galigniana NM, Béguelin W, Vicario R, Proietti CJ, Russo R, Rivas MA, Tkach M, Guzmán P, Roa JC, et al: Progesterone receptor assembly of a transcriptional complex along with activator protein 1, signal transducer and activator of transcription 3 and ErbB-2 governs breast cancer growth and predicts response to endocrine therapy. Breast Cancer Res 15: R118, 2013.
29. Boyle DP, McArt DG, Irwin G, Wilhelm-Benartzi CS, Lioe TF, Sebastian E, McQuaid S, Hamilton PW, James JA, Mullan PB, et al: The prognostic significance of the aberrant extremes of p53 immunophenotypes in breast cancer. Histopathology 65: 340-352, 2014.
30. Coates AS, Millar EKA, O'Toole SA, Molloy TJ, Viale G, Goldhirsch A, Regan MM, Gelber RD, Sun Z, Castiglione-Gertsch M, et al: Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: Results from IBCSG trials VIII and IX. Breast Cancer Res 14: R143, 2012.
31. Lee E, Nichols P, Groshen S, Spicer D and Lee AS: GRP78 as potential predictor for breast cancer response to adjuvant taxane therapy. Int J Cancer 128: 726-731, 2011.
32. Yu KD, Huang AJ, Fan L, Li WF and Shao ZM: Genetic variants in oxidative stress-related genes predict chemoresistance in primary breast cancer: A prospective observational study and validation. Cancer Res 72: 408-419, 2012.
33. Roller C and Maddalo D: The molecular chaperone grp78/bip in the development of chemoresistance: Mechanism and possible treatment. Front Pharmacol 4: 10, 2013.
34. Health Quality Ontario: Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: An evidence-based and economic analysis. Ont Health Technol Assess Ser 10: 1-57, 2010.
35. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009, 2002.
36. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B and Senn HJ; Panel members: Strategies for subtypes -dealing with the diversity of breast cancer: Highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22: 1736-1747, 2011.
37. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML and Perou CM: The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13: 2329-2334, 2007.
38. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, et al: Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11: 5678-5685, 2005.
39. Raiter A, Yerushalmi R and Hardy B: Induction of cell surface GRP78 contributes to apoptosis in triple negative breast cancer cells. Oncotarget 5: 11452-1163, 2014.